The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes

Introduction: The reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HCT) depends on multiple factors such as the conditioning regimen, age, stem cell source, and graft-versus-host disease (GVHD). Patient with chronic GVHD (cGVHD) can remain B-cell deficient even 1 year after allo-HCT. Although hypogammaglobulinemia post-transplant has been suggested as a poor prognostic factor for survival and transplant-related mortality (TRM), very little data has been published in the recent decade in the field of reconstitution of B-cell repertoires and hypogammaglobulinemia, particularly after the introduction of peripheral blood stem cell allo-HCT and in vivo T-cell depletion. This study aimed to identify the risk factors for hypogammaglobulinemia and evaluate the association between hypogammaglobulinemia and transplant outcomes in adult allo-HCT population. Methods: We retrospectively reviewed 339 consecutive patients who received allo-HCT between 2009 and 2012 at the Princess Margaret Cancer Centre, Toronto, Canada. At lest one measurement of immunoglobulin level was available in 157 patients between 3 months and 1 year post allo-HCT. IgG hypogammaglobulinemia (hypo-IgG) was defined as IgG <7g/L. The Kaplan-Meier method was used for OS, and cumulative incidences considering competing risks were calculated for NRM and relapse. The independent student’s t-test was used to compare mean IgG levels in each subgroup. The Χ2 test was used to identify the risk factors for hypo-IgG in univariate analysis and binary logistic regression was used in multivariate analysis. Multivariate analysis for OS was performed using the time-dependent cox proportional hazard model with cGVHD as a time-dependent covariate. Fine-Gray proportional hazard regression for competing events were used for NRM in multivariate analysis. Results: The mean values of IgG were 6.67±0.41g/L (n=103) at 3 months, 6.93±0.53g/L (n=94) at 6 months, and 8.34±0.49g/L (n=136) at 1 year post allo-HCT. The proportions of patients with hypo-IgG (<7g/L) among those with available IgG level at the select time-points were 59.2% at 3 months, 59.6% at 6 months and 44.9% at 1 year. Patients with lymphoid malignancies showed a lower IgG level at 3 months than those with other diseases (5.12g/L vs 7.25gL, p=0.041). Non-T-cell depletion (non-TCD) was associated with lower IgG levels at 6 months and at 1 year: 5.83g/L vs 8.98g/L at 6 months (p=0.004) and 6.97g/L vs 10.94g/L at 1 year (p<0.001). The presence of previous acute GVHD (aGVHD) grades 2-4 at 6 months was associated with a lower IgG level at 6 months (5.21g/L vs 8.66 g/L, p=0.001), but cGVHD at 6 months was not. However, a lower level of IgG at 1 year was observed among patients who developed cGVHD by 1 year than those who did not (7.79 g/L vs 10.38g/L, p=0.031). The proportion of patients with hypo-IgG at 6 months was significantly higher in the lymphoid malignancies group (78% vs 56%, p=0.049), in the non-TCD group (71% vs 39%, p=0.003), in patients with aGVHD grades 2-4 (81% vs 38%, p<0.001) and with cGVHD (71% vs 50%, p=0.056). Binary logistic regression identified the following variables as independent risk factors for hypo-IgG at 6 months; non-TCD (hazard ratio (HR) of 3.61, p=0.16), aGVHD grades 2-4 (HR 8.45, p<0.001) and cGVHD (HR 3.31, p=0.025). Overall survival at 2 years post allo-HCT was significantly lower in the group with hypo-IgG (n=56) than those with a normal IgG level (n=38) at 6 months (54.5% vs 86.6%, p=0.001). NRM at 2 years was also significantly higher in the hypo-IgG group than in the normal IgG group at 6 months (44.0% vs 3.6%, p<0.001). There was no difference in the relapse rate at 2 years between the two groups. Multivariate analysis demonstrated that hypo-IgG at 6 months (HR 6.10, p=0.006) and aGVHD grade 2-4 (HR 3.23, p=0.31) were adverse prognostic factors while reduced-intensity conditioning (HR 0.27, p=0.028) and time-dependent cGVHD (HR 0.194, p=0.001) were associated with better OS. Furthermore, cGVHD was associated with lower NRM (HR 0.27, p=0.004) and hypo-IgG at 6 months was associated with higher NRM (HR 20.0, p=0.004). Conclusion: A significant number of patients remain hypogammaglobulinemic at 6 months and even 1 year post allo-HCT. Non-TCD and acute and chronic GVHD were identified as risk factors for hypogammaglobulinemia. Hypogammaglobulinemia at 6 months was found to adversely affect OS and NRM. Disclosures No relevant conflicts of interest to declare.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.